Login / Signup

Acquired Resistance to Immune Checkpoint Blockade Therapies.

Xianda ZhaoDechen WangmoMatthew RobertsonSubbaya Subramanian
Published in: Cancers (2020)
Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.
Keyphrases
  • clinical trial
  • healthcare
  • mouse model
  • randomized controlled trial
  • stem cells
  • dna methylation
  • squamous cell carcinoma
  • genome wide